Consistent response
Achieve a consistent platelet response
with Doptelet1
In the Phase 3 trial, the median platelet count was consistently higher with Doptelet vs placebo from day 8 (80.5 x 109/L vs 8 x 109/L).1
Median platelet count over time1
Figure is drawn up by Sobi as a rendering of figure 3A p 486 in ref 1.
Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.2
Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).2
ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.
References
1. Jurczak W et al. Br J Haematol. 2018; 183(3):479–490. 2. Doptelet Summary of Product Characteristics. 22/05/2025
PP-29424
Other sites